Allogene Therapeutics (NASDAQ:ALLO)‘s stock had its “buy” rating reaffirmed by equities research analysts at William Blair in a research report issued to clients and investors on Monday, AnalystRatings.com reports.

Several other analysts have also commented on the stock. Zacks Investment Research lowered shares of Allogene Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, April 8th. Piper Jaffray Companies began coverage on shares of Allogene Therapeutics in a research report on Friday, March 29th. They set an “overweight” rating and a $50.00 price target on the stock. Raymond James began coverage on shares of Allogene Therapeutics in a research report on Thursday, March 14th. They set an “outperform” rating and a $40.00 price target on the stock. JPMorgan Chase & Co. restated a “hold” rating and set a $29.00 price target on shares of Allogene Therapeutics in a research report on Monday, March 11th. Finally, Cowen restated a “buy” rating on shares of Allogene Therapeutics in a research report on Friday, March 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $36.83.

ALLO stock traded down $0.41 during midday trading on Monday, hitting $25.91. 4,090 shares of the stock traded hands, compared to its average volume of 517,968. The firm has a market cap of $3.19 billion and a PE ratio of -3.93. Allogene Therapeutics has a 1-year low of $21.67 and a 1-year high of $35.55.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings results on Friday, March 8th. The company reported ($0.35) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.10). Research analysts predict that Allogene Therapeutics will post -2.13 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $27,000. Legal & General Group Plc acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $89,000. Partner Investment Management L.P. acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $135,000. Citigroup Inc. acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $152,000. Finally, Strs Ohio acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $156,000. Institutional investors and hedge funds own 51.60% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.

Further Reading: Mutual Funds

Analyst Recommendations for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.